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Despite countless advances in recent decades across various in vitro, in vivo and in silico tools, 
anticipation of whether a drug will show a human food effect (FE) remains challenging. One means to 
predict potential FE involves probing any dependence between FE and drug properties. Accordingly, 
this study explored the potential for two machine learning (ML) algorithms to predict likely FE. Using a 
collated database of drugs licensed from 2016-2020, drugs were classified into three groups; positive, 
         
negative or no FE. Greater than 250 drug properties were predicted for each drug which were used to 
train predictive models using Support Vector Machine (SVM) and Artificial Neural Network (ANN) 
algorithms. When compared, ANN outperformed SVM for FE classification upon training (82%, 72%) 
and testing (72%, 69%). Both models demonstrated higher FE prediction accuracy than the 
Biopharmaceutics Classification System (BCS) (46%). This exploratory work provided new insights 
into the connection between FE and drug properties as the Octanol Water Partition Coefficient 
(S+logP), Number of Hydrogen Bond Donors (HBD), Topological Polar Surface Area (T_PSA) and 
Dose (mg) were all significant for prediction. Overall, this study demonstrated the utility of ML to 




Oral Drug Delivery, Bio-Enabling Formulations, Food Effect, Machine Learning. 
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FE, Food Effect; AUC, Area Under the Curve; Cmax, peak plasma concentration; Tmax, time to peak 
plasma concentration, BCS, Biopharmaceutics Classification System; BDDCS, Biopharmaceutical 
Drug Disposition Classification System; PBPK, Physiologically Based Pharmacokinetic Modelling; 
M&S, Modelling and Simulation, ML, Machine Learning; SVM, Support Vector Macines; ANN, Artifical 
Neural Networks, EMA, European Medicines Agency; FDA, Food and Drug Administration; MAD, 
Maximum Absorbable Dose; S+logP, the Octanol Water Partition Coefficient; HBD, Hydrogen Bond 
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Aqueous Solubility; D/S, Dose/Solubility Ratio; MWt, Molecular Weight; RB, Rotatable Bonds; MCC, 
Matthews Correlation Coefficient; logHLC, logarithm of the air-water partition coefficient (Henry's Law 
Constant at 25°C); F_HBP, Population Average Number of Protons Available for Hydrogen Bonding 







         
 
Introduction 
It is widely recognised that concomitant administration of oral dosage forms with food can alter drug 
pharmacokinetic profiles (1-3). As oral dosage forms are both widely and often chronically 
administered, understanding of the biological processes triggered by food consumption and its 
complex and drug-specific impact on oral bioavailability. The numerous underlying mechanisms by 
which food exerts this effect on drug absorption include physiological changes in pH, gastric emptying 
times, fluid volumes, bile salt concentrations and intestinal enzyme activity, in addition to specific food 
effects including binding, metabolism or interference with transporters (1, 3, 4). The clinical 
consequences of these changes are assessed through comparison of pharmacokinetic parameters 
describing the rate and extent of bioavailability i.e. peak plasma concentration (Cmax), time to peak 
plasma concentration (Tmax) and area under the curve (AUC) in both the fed and fasted state (5). A 
food effect (FE) is defined as when the 90% confidence intervals for the ratio of population geometric 
means, based on log transformed data, for either AUC0→∞ or Cmax fall outside the 80–125% 
bioequivalence limits relative to the same formulation administered in the fasted stated (5). These FE 
studies are subject to stringent regulatory requirements (5, 6), and the consequences of food-
mediated effects on bioavailability have been widely reported (3, 7-12).  
Previous research that 40% of drugs licensed between 2010 and 2017 displayed significant FE (1) 
suggests that within the current drug development paradigm, anticipation of the impact of food on 
drug absorption is pertinent. Moreover, in addition to guiding the design of improved formulations that 
are food effect resistant, this information is fundamental to optimise exposure of medicines with 
narrow therapeutic ranges in a clinical setting, to meet strict fed state bioequivalence study 
requirements of international regulatory authorities and reduce costs associated with product failures 
due to variability in exposure (1, 3, 7, 13). Consequently, the ability to predict and anticipate FE on 
oral drug delivery is of immense value to drug development. To date, extensive mechanistic tools 
spanning a wide range in vitro, in vivo and in silico methods to predict FE have been described in 
literature (14-18). Typically, drug performance under fasted and fed conditions are anticipated in vitro 
with dissolution tests in biorelevant media mimicking the human gastrointestinal environment (19-21) 
while in vivo predictions using various animal models (14, 16, 22), including canine and porcine 
examples, have also been employed, along with drug solubility testing in aspirated intestinal fluids 
(15, 23). However, despite the varying levels of success achieved by these methods, the multifaceted 
factors associated with drug, meal type and physiological conditions mean that, as of yet, no 
universally comprehensive approach for FE prediction has been found and that all current models 
exhibit limitations. 
Owing to the limitations of in vitro methods, and the challenges in performing in vivo pharmacokinetic 
studies, in silico methods have emerged as the “go-to” approaches for predictive biopharmaceutics 
(24). Drug classification tools comprising rules of thumb based on drug biopharmaceutical properties, 
         
and both the Biopharmaceutics and Biopharmaceutical Drug Disposition Classification Systems (BCS 
and BDDCS), provide simple guides to anticipate FE based upon related drug physicochemical 
properties (14, 25, 26). While such approaches provide a readily accessible prediction of likely FE, the 
relatively low accuracy and precision of these predictions has necessitated the development of 
mechanistic and data driven in silico models of FE (9).  Physiologically based pharmacokinetic 
(PBPK) models lie at the centre of this diversifying modelling and simulation (M&S) toolbox, and have 
achieved increasingly accurate predictions of FE (27-30). Using mathematical equations to model 
physiological processes and anatomical parameters, these compartment-based absorption models 
mechanistically simulate a drugs plasma concentration-time profile in the fasted and fed states and 
can be applied in both pre-clinical studies with further potential application as decision-making aids for 
regulatory agencies (31). While PBPK models require comprehensive data about the physiological, 
biochemical, and physicochemical processes that occur, data-driven modelling tools which establish 
statistical relationships between FE and drug molecular properties, signify complementary additions to 
this ever-expanding M&S toolbox without the need for such. To date several attempts, spanning the 
last three decades, have been made to probe dependence between FE and drug physicochemical or 
molecular properties. These include quantitative linear correlations of AUC with individual drug 
properties (32) and a tool for computational biopharmaceutical profiling of ligands, based on predicted 
increases in fed state simulated intestinal fluid (FeSSIF) solubility to signal a positive FE (17). Finally, 
qualitative computational models predicting if a drug displays a positive, negative, or no FE according 
to the AUCfed/AUCfasted ratio, have also been published, using logistic regression (33) and more 
recently decision tree analysis (34).  
Consequently, while modelling efforts to correlate the effect of food on AUC with drug properties exist, 
the application of multiple machine learning (ML) classification algorithms to predict FE remains 
unexplored. Support Vector Machine (SVM) classification and Artificial Neural Network (ANN) 
algorithms have been gaining interest across various facets of drug design and development, 
supporting streamlined and decision-based pre-clinical testing (35-41). SVM is a pattern recognition 
method widely used in data mining which works by finding an optimal separation line (hyperplane) 
which accurately separates and maximises the margins between two or more classes. Separation of 
non-linear data is also achievable through kernel functions which map the original data to a higher-
dimensional “feature space” facilitating linear separation, as previously described (42, 43). While as a 
ML algorithm, ANN detects complex non-linear relationships between datasets, by mimicking basic 
human biological information processing methods. Adopting a general structure consisting of an input 
layer, hidden layer(s), output layer and using activation functions and connection weights, nodes 
(artificial neurons) from the input layer send data to the hidden and output layers through weighted 
connections (“synapses”) to predict Y, as described in detail previously (44, 45). Using these ML 
algorithms, the broad objective of this work sought to develop a in silico model which could identify 
important drug properties for accurate FE prediction. Here, drugs were classified as displaying a 
positive, negative or no FE according to change in the extent of drug absorption (AUC) in the fed 
versus fasted states. Using a collated database of newly licensed drugs from 2016-2020, both SVM 
and ANN were employed to explore any relationship between the three FE classes and drug 
         
properties. The study design facilitated investigation into the prevalence of FE among drugs licensed 
in the last 5 years, while also assessing if either ML algorithm or the BCS classification tool provided 
the highest prediction accuracy for this dataset. Accordingly, this study provides the first evidence of 
the capacity of ANN and SVM to facilitate early anticipation of likely FE.  
Methods 
Database collation 
The drug database used in this study was obtained from drug products licensed in the European 
Medicines Agency (EMA) and Food and Drug Authority (FDA) between January 2016 and December 
2020. The database of original new drug applications (NDA’s) on the FDA website was searched by 
month from January 2016 to September 2020 along with the European Public Assessment Report 
(EPAR) of the EMA licensed products each year from 2016-2020. Exclusion criteria were any non-oral 
product, any biological product, any modified release product, any product where no FE information 
was available, any generic of a previously authorised product or any authorisation submission 
referring purely to changes of product indication. The products eligible for analysis were new 
molecular entities (NME), new combination products and reformulations of products which have been 
previously marketed. General information recorded included year of licensing, generic name, 
commercial name and any label restriction of the drug administration regarding food. Information 
regarding FE on absorption was obtained from the product EPAR or FDA label for each product 
where the ratios of AUCfed/AUCfasted were recorded. In cases where the documentation stated a 
product showed no change or a non-significant change in AUCfed/AUCfasted, with no values or ratios 
provided, a value of 1 was assigned. As FE information was obtained from regulatory submissions 
only, variables related to meal composition that might affect the interpretation of results were 
minimised.  
 
Food Effect Classification  
In this study drugs were predicted to belong to one of 3 FE classes designated according to the 
change in the extent of drug absorption in the fed versus fasted state (AUCfed/AUCfasted) alone, with 
“positive” referring to significantly increased and “negative” referring to significantly decreased extent 
of drug absorption in the fed state. This lone classification parameter was chosen as information 
regarding Cmax was more frequently omitted from EPARs and FDA drug labels. Previous comparative 
studies also used this classification criterion, and the toxicity, efficacy and clinical significance of 
numerous drugs including those which are chronically dosed, correlates better with total exposure 
(AUC) than Cmax (1, 32). The FE ratio (AUCfed/AUCfasted) was obtained for all drugs in the final dataset 
(141 drugs). A positive or negative FE was considered significant if the ratio fell outside 80–125% in 
reference to the currently accepted 90% CI for the ratio of population geometric means between fed 
and fasted treatments for concluding a lack of food-effect (5). Drugs with AUCfed/fasted >1.25 were 
classified with a “positive FE”, AUCfed/fasted between 0.8-1.25 were deemed to have “no FE” and 
         
AUCfed/fasted <0.8 a “negative FE”. The final database of 141 drug compounds consisted of 44 Positive 
FE, 80 No FE and 17 Negative FE drugs.  
 
Compilation of Physicochemical Descriptors 
More than 250 descriptors for each drug were obtained from ADMET Predictor 9.5 (Simulations Plus, 
USA). Molecular structures were acquired as smiles from PubChem and used as inputs for the 
ADMET Predictor software (Version 9.5, Simulations Plus, California, USA) to calculate the molecular 
descriptors. A conscious effort was made to ensure repetition of drug properties found to be 
significantly correlated with food effect in previously published reports, to facilitate comparisons (32-
34). The drug dosage strength used in the FE bioequivalence study for each drug was obtained from 
the EPAR or FDA product label respectively. A maximum absorbable dose (MAD) was calculated 
using a predicted fasted state simulated intestinal fluid (FaSSIF) solubility, again using ADMET 
Predictor, using the equation described previously (46). The Dose Solubility ratio was calculated using 
the dose as described above divided by an aqueous drug solubility predicted from ADMET Predictor.  
 
Statistical analysis 
Prior to employment of ML, to analyse any linear univariate correlations between FE classification and 
selected drug properties, a stepwise statistical analysis approach, as described previously (47), was 
adopted using SPSS (IBM Corporation, US) on the full drug database. It was hoped that these 
preliminary results could inform which properties may be significant for ML prediction. In brief, 
frequency distributions of the variables were graphed for each FE classification (positive, negative, no 
FE) and normality was checked visually with Q-Q and P-P plots. Ratios of samples sizes between the 
3 groups were obtained. Variances of the datasets were analysed and compared to Levene’s Test for 
Equality of Variances. A p-value <0.05 indicated a violation of equal variance. The null hypotheses 
were that no statistical differences were seen in a drug property between drug classes. Three 
separate comparisons were made i.e. Negative versus No FE, No FE versus Positive, Positive versus 
Negative. Comparison between groups were made using the t-test, Welch’s test or Bootstrap 
independent samples test (5000 samples.) A p-value of 0.05 was used as the significance level for all 
tests. Boxplots were produced to facilitate visual interpretation of the data again using SPSS (IBM 
Corporation, US) and descriptive statistics including Median, Mean, Standard Deviation of Mean, Q1, 
Q3, Minimum, Maximum, Variance were obtained for each drug property for the 3 groups. The 
properties selected were S+logP (Octanol Water Partition Coefficient), HBD (Number of Hydrogen 
Bond Donors), HBA (Number of Hydrogen Bond Acceptors), T_PSA (Topological Polar Surface 
Area), Dose (mg), S+logD (Partition Coefficient pH 7.4), S+Sw (Aqueous Solubility), MAD (Maximum 
Absorbable Dose), D/S (Dose/Solubility Ratio), MWt (Molecular Weight) and RB (Rotatable Bonds). 
 
         
BCS Classification 
The BCS class of the drugs studied were obtained where available from the EPAR, FDA label or from 
literature. Fleisher et al. (4) previously described the general trend of FE on drug absorption (AUC) 
based on BCS classification where, BCS Class I compounds are likely to have no FE; BCS Class II 
compounds are likely to have a positive effect; BCS Class III compounds are likely to exhibit a 
negative effect while there is insufficient evidence for any clear identifiable trends for BCS Class IV 
compounds. Further separation of drugs within BCS classes as previously recognised (15), was not 
conducted to facilitate comparisons to a previously published analysis (33). Accordingly, the database 
was classified into these 3 FE categories, while BCS class 4 drugs were disregarded for this portion 
of the analysis.  
 
Machine Learning/Model Development 
FE classifications were predicted using two ML algorithms, ANN and SVM. To facilitate direct 
comparison of the predictive power of both algorithms the same training:test split was used. Principal 
Component Analysis (PCA) using the Unscrambler XI (Camo Analytics, US) was applied for a 
randomised assignment of training:test data. Training set criteria was that it covered the chemical 
space of the test set and ensured an almost equal representation of positive, negative and no FE 
drugs in the training set to avoid any potential for classification bias. Such imbalance in datasets has 
proved to be a widely reported obstacle to classification problems in ML in the past (42). In 
accordance with previous reports of classification prediction using ML algorithms (41, 48), initial 
variable reduction was conducted. Either a one-way ANOVA analysis with Tukey Multiple 
comparisons test (parametric) or Kruskal-Wallis analysis with Dunn’s multiple comparison test (non-
parametric) were applied to the training data. Variables with a p-value less than 0.05 for at least one 
class pair in the respective post tests were highlighted for further investigation. A correlation analysis 
of these identified variables was carried out with highly correlated variables clustered into the same 
group and the most significant variable of the group chosen for inclusion in the model development. 
Final models as well as BCS predictions were compared in terms of various accuracy statistics 
including, overall accuracy of prediction, as well as sensitivity, precision, specificity and Matthews 
Correlation Coefficient (MCC) for each FE class, as previously defined (49), where TP, FP, TN and 
FN refer to true positive, false positive, true negative and false negative results respectively. MCC 
was previously suggested as a reliable statistical metric for ML performance quality evaluation (50). A 
high MCC score (close to 1) is only achieved if the model obtained good results in all four confusion 
matrix metrics (TP, FP, TN, FN).  
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Support Vector Machine Classification 
A SVM algorithm was used to build a classification prediction model using Unscrambler XI (Camo 
Analytics). Resulting variables from the initial variable reduction protocol were mean centred, de-
identified and standardized through scaling by standard deviation. Variables were added one-by-one 
to assess which combinations produced the highest accuracy in both the training and test sets. C-
SVC was used, where as part of the optimisation procedure the optimum values of key parameters of 
the regularization parameter C and gamma were sought from a grid search, performed across 10 
orders of magnitude in logarithmic scale. In this grid search these key parameters were varied 
systematically to monitor which combination provided the highest classification accuracy in training 
and cross validation. This grid search was repeated for each variable combination using various 
kernel types (linear, polynomial, radial basis function and sigmoid) until the combination of kernel, C, 
gamma and input variables resulting in the best classification performance was obtained. The 
variables with the highest contribution to SVM classification were interpreted from the loadings plot of 
the PCA analysis which mapped the multidimensional data into a two-dimensional space. 
 
Artificial Neural Networks 
Multilayer Perception Artificial Neural Networks (MLP-ANN) were produced using SPSS Statistics 
(Version 26, IBM Corporation, US). The output layer consisted of three responses/categories: 
positive, negative or no FE. After initial variable reduction, as described above, the remaining 
significant variables were rescaled through standardisation where values were converted to their z-
scores. Hyperbolic tangent was chosen as the activation function for the hidden layer, while an 
identity output function was used as the output layer activation function (51). Supervised learning 
using the Scaled Conjugate Gradient algorithm was chosen (52). Batch training was selected. 
Topologies with only one hidden layer were considered. The optimum number of neurons in the 
hidden layer was identified following a systematic trial-and-error approach were the number of 
neurons in the hidden layer were manually altered between 2 and 50, with runs being performed in 
triplicate. The optimal network size was chosen from the solution which resulted in the highest 
prediction accuracy in the training and test sets. All combinations of the significant variables were 
tested to ascertain which combination produced the highest prediction accuracy. This procedure was 
repeated until no improvement in model performance was observed. The relative contributions of 
each variable in the final network were elucidated from the Normalised Importance Chart. 
         
 
         
Results 
Analysis of Trends in Physicochemical Descriptors between Food Effect Classifications 
 
A selection of well-known molecular and physicochemical properties of drugs licensed in the last five 
years were statistically compared with respect to the three FE classes. It was anticipated that as a 
result of this preliminary analysis of the entire dataset, any significant differences in properties 
between classes could inform which properties may be significant for subsequent ML prediction. 
Tabular results of the statistical analysis are shown in Supplementary Materials. A visual 
representation of properties which demonstrated significant differences is illustrated in Figure 1.  
Upon statistical analysis, the properties of S+logP, HBD, T_PSA, Dose, S+Sw, S+logD, MWt, D/S and 
MAD were all significantly different for at least one pairing i.e. negative versus positive, negative 
versus no FE or positive versus no FE. Of these, 6 properties, namely S+logP, HBD, Dose, S+Sw, 
D/S and S+logD were found to be significantly different between drugs classified as having either a 
positive or negative FE. In particular, the mean S+logP value was observed to be almost 2.5 times 
greater for positive FE drugs. Conversely, it was observed that drugs with a positive FE could be 
differentiated from drugs which displayed no FE in terms of the 8 properties of S+logP, T_PSA, Dose, 
S+Sw, S+logD, MWt, D/S and MAD. Where the median dosage strength for positive FE drugs was 
four times higher than that of drugs with no FE (200mg vs. 50mg). Finally, drugs classified as either 
displaying a negative or no FE appeared more difficult to differentiate as only three properties were 
found to be statistically different for this pairwise comparison, namely S+logP, HBD and T_PSA, 
where the median number of HBD for negative FE drugs was double that of no FE (4 vs 2). Overall, it 
was observed that only one property, S+logP, was found to be significantly different between the all 
three classification groups (Figure 1). Furthermore, the properties of HBA, RB, were not found to be 
significantly different between any of the three pairwise comparisons. 
 
Food Effect Prediction using BCS Classification  
The dataset collated in this study consisted of 61/141 (43%) drugs displaying either a significant 
positive or negative FE. Previous reports indicate that BCS classifications (BCS Class I, II, III), using 
dose:solubility ratio and extent of absorption, can aid identification of likely FE, and such an approach 
was investigated to facilitate comparison of this simple classification rule of thumb versus data-driven 
ML techniques (4). In this study, using classifications based on the BCS, a poor overall accuracy of 
prediction (46%) was obtained. While the sensitivity of the method was acceptable for positive (87%) 
and negative (69%) FE drugs, relating to lower numbers of false negative classifications, the same 
could not be said for the no FE class where only 22% of drugs found to display no FE were BCS class 
1 (Figure 2). While in terms of precision i.e. positive prediction rate, using the BCS tool, poor results 
were seen for positive (41%) and negative FE (35%) drugs with a poor rate of specificity also seen for 
         
the positive FE group (49%). Finally, in terms of MCC, scores close to zero of 0.3 (positive), 0.2 
(negative) and 0.2 (no FE) respectively were calculated (Figure 2). Therefore, these results suggest 
that use of the BCS tool to predict FE classification results in high relative amounts of either false 
positive or false negative predictions.   
 
Applying ANN and SVM to Predict Food Effect Classification.  
Two ML algorithms, ANN and SVM were employed to qualitatively predict if a drug displayed positive, 
negative or no FE. Using the SVM algorithm, the optimum model required 6 drug properties for 
prediction, namely S+logP, HBD, T_PSA, dose, logarithm of the air-water partition coefficient (Henry's 
Law Constant at 25°C) (logHLC) and population average number of protons available for hydrogen 
bonding divided by the number of non-hydrogen atoms (F_HBP). Using the radial basis function 
(RBF) kernel which outperformed the other kernel functions tested, results demonstrated that the 
SVM model could correctly predict FE classification of the training and set sets with 72% and 69% 
overall accuracy respectively (Figure 3). No FE drugs were predicted with the highest sensitivity upon 
both training (86%) and testing (71%) (Supplementary Materials), demonstrating better or 
comparative performance to ANN in these cases. Conversely, it was observed that the SVM algorithm 
was less successful in differentiating drugs with a negative FE compared to the ANN model described 
below (59%). In terms of precision, positive prediction rates of 79%, 91% and 60% were observed for 
the positive, negative and no FE groups (Figure 3). The SVM model showed the highest specificity in 
negative FE prediction (98%) where the lowest specificity was calculated for no FE drugs (69%). 
Intermediate MCC scores of 0.6, 0.7 and 0.5 were observed for the positive, negative and no FE 
classes respectively. Upon interpretation of the PCA correlations loading plot, HBD was the most 
influential property for classification prediction using this SVM-based model.  
ANN model development resulted in an optimum three-layer feed forward network denoted MLP 4-13-
3 (Figure 4). This network consisted of a single input layer with four descriptors, octanol water 
partition coefficient (S+logP), number of hydrogen bond donors (HBD), Topological Polar Surface 
Area (T_PSA) and Dose (mg), a single hidden layer with 13 nodes and an output layer with three 
output variables representing the 3 possible FE classifications (positive, negative, no FE). This 
network achieved high overall prediction accuracy in both the training (82%) and test sets (72%) 
(Figure 3). In terms of the individual classes, in contrast to the SVM model, drugs displaying positive 
FE could be distinguished the easiest displaying the highest sensitivity rates in both the training (91%) 
and test sets (73%), while the lowest sensitivity was seen for the no FE group (76% training, 71% 
test). For the positive, negative and no FE groups respectively, the precision of the predictions were 
83%, 93% and 73%, specificity was 90%, 98% and 85% and higher MCC scores of 0.8, 0.8 and 0.6 
closer to 1 were obtained (Figure 3). From the normalised importance chart, the most important 
property for prediction was S+logP, followed by T_PSA, HBD and Dose. However, all properties 
displayed over 67% normalised importance to prediction.  
         
Overall, relatively similar overall prediction accuracy was achieved using both ML algorithms, as ANN 
marginally outperformed SVM. The proposed ANN network demonstrated equivalent or higher 
sensitivity, precision and specificity statistics for all but one metric for the three FE classes. In terms 
MCC, which have been reported as a more reliable overall performance evaluator, comparatively 
higher scores were observed for the ANN model. Resultantly, considering these superior and more 
consistent classification results along with the requirement for less input descriptors, it was concluded 


























The significant effects of concomitant food intake on the pharmacokinetics of many drugs highlights 
the importance of FE predictions The capability to predict FE early in the drug development process 
can  potentially expedite progression of drug products through pipelines, and streamline the 
regulatory approval process through identifying where clinical FE studies may or may not be required. 
As a result, the earliest possible elucidation of important drug properties which indicate a likely FE is 
vital as it was seen in this study that 43% of drugs licensed in the last 5 years reported either a 
significant positive or negative FE. While various efforts, dating as far back as 1996 (53), have been 
made to correlate FE with drug properties, the purpose of this study was to investigate if modern ML 
capabilities could predict the FE classification of drugs. As the dataset employed embodied drugs 
brought to market in the last 5 years, which are largely diverse in terms of their structural, 
physiochemical and pharmacokinetic properties, it was analysed if these ML algorithms could yield 
predictive tools relevant for the contemporary drug development landscape.  
Our study demonstrated the capability of ML algorithms to predict FE classification based on 
physicochemical drug descriptors. Upon comparison of the two ML algorithms, results suggested that 
while both approaches demonstrated capacity for prediction, ANN outperformed SVM. The optimum 
ANN, containing 1 hidden layer of 13 nodes and using 4 input properties (S+logP, T_ PSA, HBD, 
Dose), yielded strong overall accuracy in classification for both training (82%) and test sets (72%). 
Comparatively, the SVM model which employed 6 input properties (S+logP, T_PSA, HBD, Dose, 
F_HBP, logHLC) for prediction, did also demonstrate relatively good accuracy upon training (72%) 
and testing (69%). However, in terms of the performance metrics analysed i.e. precision, sensitivity, 
specificity and MCC, the ANN model proved either superior or equivalent to SVM in 11/12 cases, 
including MCC scores closer to 1 for all three classes. The exact reason for the improvement in 
performance metrics and requirement for less inputs for ANN, while difficult to pinpoint, may be 
attributable to the varying mathematical approaches used by both methods to classify this non-linearly 
separable dataset and map the data to higher dimensional spaces, i.e. kernel tricks (SVM) and non-
linear activation functions (ANN) (44, 49, 54, 55). While the comparative accuracy of SVM versus 
ANN modelling is dependent on the specific dataset involved, the easily interpretable, readily 
obtainable, and widely recognisable nature of the four properties used in the ANN model to 
formulation scientists expands its applicability in a preclinical setting, as at this time only limited 
resources and preliminary information are available regarding a model compound. Accordingly, this 
study supports the application of ML algorithms, in particular ANN, to provide accessible tools for FE 
prediction of newly licensed drugs.  
         
Our models identified key physicochemical and molecular properties which contribute to the 
classification of newly licensed drugs according to the likely effect of food on extent of drug 
absorption. While the ANN model found four properties of S+logP, Dose, HBD and T_PSA to be 
noteworthy, using SVM the properties of logHLC and F_HBP were also required. The inclusion of 
S+logP as the most important property for ANN prediction matches observations from our preliminary 
statistical analysis. There S+logP, a widely used drug parameter used in PBPK modelling (56), was 
the only property significantly different between all three pairwise comparisons (Figure 1). While 
another type of partition coefficient, logHLC was also significant for SVM modelling, S+logP or 
increasing drug lipophilicity in particular has previously been linked with increased susceptibility to 
positive FE (17, 32, 57), through the increased dissolution and solubilisation effects of food for 
lipophilic drugs. This is a partition property, while a hypothesis for its significance may relate to 
ingestion of fatty foods resulting in greater partitioning of lipophilic drugs between the digestion 
phases which could be related to the kinetics of partition between octanol and water. Using a cohort 
of pre-2005 drugs, Singh et al. found a significant positive correlation between AUC ratio and logP, 
where the positive effect of food was more pronounced for lipophilic drugs (32). In agreement, in this 
study, we observed that 41% of drugs with a positive FE had S+logP values >4, with 84% >2. Gu et 
al. and Omachi et al. have also successfully utilised logP or the closely related logD as a critical 
parameter to predict FE on AUC using both logistic regression and decision tree analysis (33, 34). 
Nevertheless, while the significance of S+logP in our model suggests the importance of a lipophilicity 
indicator to predict FE on AUC, caution has previously been advised in terms of using this blanket 
generalisation of likely positive FE for all PWSD as exceptions exist (32). In addition to its importance 
as a partition property, the requirement for S+logP may also reflect its significance to predict other 
biopharmaceutical properties such as membrane permeability, as it is possible that some dietary 
foods may affect permeability, however, it is unlikely that this would be unique to certain drugs. 
Lipophilicity has previously been correlated with permeability measurements for compounds which 
are passively transported (58-62).  
In this study S+logP alone did not prove sufficient for accurate prediction of FE, as other properties 
including HBD and T_PSA were found in the final models. While these were not previously significant 
parameters for FE classification using logistic regression (33), using this contemporary cohort of 
drugs ML identified their predictive abilities. Both parameters, have been formerly associated with 
membrane permeability (59), as poor permeation is suggested to be likely with drugs of PSA >140Å 
(63, 64), where T_PSA is the commonly used PSA descriptor (17), and an excessive number of HBD 
groups impairs permeability across a membrane bilayer (65-67), as specified by a cut-off of 5 in 
Lipinski’s rule of 5 developability criteria (59). Both parameters were used previously along with logP, 
to predict human jejunal permeability (Peff) using partial least squares regression (60). It could be 
suggested that the role of both T_PSA and HBD in the ML models was to aid identification of drugs 
with negative FE as HBD and T_PSA demonstrated the highest mean values for the negative FE 
class upon preliminarily statistical analysis (Figure 1). This finding correlates well to the Fleisher et al. 
summary of FE prediction based on BCS class where Class 3 drugs, of poor permeability and good 
         
solubility, are likely to exhibit negative FE (4). Such negative food effects were previously associated 
with highly hydrophilic drugs displaying a narrow window of absorption (18, 33).  
Dose was also a significant parameter in classify drugs by food effects on AUC. Upon early statistical 
analysis, it was observed that over 18% of drugs displaying a positive FE used a dose >500 mg in 
their respective pharmacokinetic studies, compared to 0% and 6.25% of negative and no FE drugs 
respectively, with 59% of this positive class using a dose >200 mg. While the exact reason for this 
substantial difference in dosage strength between classes is unknown, previously a logistic regression 
model found dose number and MAD to be significant for FE classification (33). However, when tested 
neither were found to be significant in our ML models. In addition, the Dose/Solubility ratio of a drug 
was previously significantly correlated with AUC however, in our analysis neither this ratio nor S+Sw, 
despite displaying significant differences between classes in our preliminary statistics, were important 
for ML prediction. It could be hypothesised that this dose parameter aided the prediction of positive 
FE drugs due to its ability to differentiate positive FE drugs from both negative and no FE classes in 
our initial statistical analysis (Figure 1). Overall, the properties most significant for FE classification 
demonstrate the importance of both solubility and permeability for FE prediction. These properties 
reflect widely known drug-likeness filters, drug classification systems and properties used in previous 
models for FE prediction. It is likely that any differences in significant properties compared with 
previous publications reflect the different datasets of drugs used to build the respective models, as 
this study reflects the most contemporary drug products licensed in the last 5 years.  
As previously stated, in terms of accuracy the ANN model outperformed SVM for FE classification. 
However, when compared to predictions using BCS class, both ML models performed strongly as the 
overall BCS accuracy (46%) was substantially weaker than that of the ML algorithms. BCS 
classifications appeared inadequate compared to ML in terms of consistency in precision, sensitivity, 
specificity and MCC scores. Owing in part to a large number of false positive predictions (58 drugs), 
this BCS accuracy of 46% is substantially lower than its previous 67% accuracy in classifying FE for a 
database of pre-2007 drugs (33). Possible reasons for this inaccuracy compared to pre-2007 drugs 
are unclear but may reflect that the drugs licensed between 2016-2020 represent a different chemical 
design space. While direct accuracy comparisons with the ML models are not achievable as no trends 
in FE have been suggested for BCS class IV drugs, perhaps improved predictions with the BCS tool 
could be obtained going forward with further subdivision of categories into weak acids, weak bases, 
and lipophilic compounds (15), however this was not within the scope of this study. Additionally, the 
accuracy of the ANN model compared favourably to accuracies of 80% and 66% achieved in previous 
computational approaches to predict FE classification (33, 34). Ultimately, direct comparisons of 
prediction accuracies are unachievable due to the absence of external test sets in these previous 
publications and differences in the datasets used to build the respective models. However, this work 
identifies ANN as an accurate and efficient solution in detecting correlations between FE and drug 
properties from a cohort of newly licensed drugs using only 4 well-known drug properties. In the grand 
paradigm of drug development and computational pharmaceutics this model would provide early 
indication if significant FE are relevant, allowing informed decisions in drug development. Including 
         
whether redesign of the drug candidate may be relevant based on drug properties or whether a bio-
enabling strategy should be applied, prompting subsequent application of other computational models 
such a previous example from our own group (68-71), which would give an indication as to whether a 
lipid-based formulation (LBF) or other formulation strategies which are reported to overcome FE, may 
offer a high likelihood of success.  
The effects of food on bioavailability are multifaceted, involving physiological, physicochemical and 
biochemical mechanisms, and as a result, similar to all current methods to anticipate FE, limitations of 
our models are acknowledged. By design, data-driven modelling approaches identify correlations 
between individual drug properties of the dataset and classifications, thereby facilitating prediction of 
the general physiological changes exert by food on drug absorption. However, such an approach, 
limited by the physiochemical parameters employed, cannot capture all contributing factors drug 
specific FE such as effect on metabolism, bile-micelle binding, specific chelation between food and a 
drug or activity of a specific transporter or enzyme (1, 14, 15). As understanding of such effects 
continues to grow across future studies, in line with continued improvements and understanding of 
other approaches of FE prediction, opportunities will exist to broaden the utility of these predictions to 
incorporate such factors. This aside, these current models successfully predict FE category, providing 




In this study, innovative predictive models using two ML algorithms (SVM and ANN) were developed 
which accurately predicted the FE category of drugs licensed between 2016-2020, of which 43% 
demonstrated significant FE. These models were found to possess greater prediction accuracy than 
FE predictions using the BCS criteria and performed strongly upon comparison to previously 
published tools using older drug datasets. This predictive modelling enabled key physiochemical 
parameters that contribute to the effect of food on the extent of drug absorption to be identified, 
namely S+logP, T_PSA, HBD and Dose. Therefore, this exploratory work provides a further 
mechanistic basis to understand a drugs behaviour in fed and fasted conditions using a contemporary 
cohort of licensed drugs. Of course, the rationale and requirements for FE determination will differ 
depending on the stage of drug development, be that preliminarily formulation testing or the 
investigation of specific pharmacokinetic parameters. Regardless, the ML tools, particularly the ANN 
produced in this study can facilitate screening of drug candidates for potential FE, with little cost and 
effort at the early stages of drug development, utilising only easily recognisable drug properties. 
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Figure 1 A+B: Visual representation of the statistically significant differences found between Positive, Negative 
and No Food Effect Classes as part of the preliminary statistical analysis. p-values for the statistically significant 
pairwise comparisons are shown. The dark line in the middle of the boxes is the median. The bottom and top of 
the box indicates the 25th (Q1) and 75th percentile (Q3). The T-bars are inner fences/whiskers which extend to 
1.5 times the box height. The points are outliers that do not fall in the inner fences. The asterisks are extreme 
outliers which have values greater than three times the height of the boxes. 
 
Figure 2: Visual representation of the sensitivity, precision, specificity and Matthews Correlation Coefficient 
(MCC) scores of the classification predictions (positive, negative and no Food Effect (FE)) using the 
biopharmaceutics classification system (BCS) criteria where an overall accuracy of 46% was achieved for the 
dataset. 
         
 
Figure 3: Visual comparison of the sensitivity, precision, specificity and Matthews Correlation Coefficient (MCC) 
performance metrics calculated for the optimum Support Vector Machines (SVM) and Artificial Neural Networks 
(ANN) models produced in this study to predict food effect (FE) classification.  
         
 
Figure 4: Schematic representation of the optimum multilayer perceptron (MLP) 4-13-3 Artificial Neural Network 
(ANN) produced which outperformed Support Vector Machines (SVM) for the food effect (FE) classification of 
drugs licensed from 2016-2020. H refers to hidden layer node.  
  
         
Table 1: Compilation of licensed oral medicines from 2016-2020 and their AUCfed/AUCfasted ratio, clinical 
recommendation regarding food take, BCS and Food Effect (FE) Classification. LF, MF and HF refer to Low Fat, 
Medium Fat and High Fat Meals respectively, 
*
refers to the 90% CI limits and 
**























Taken on an empty stomach, at least one hour before 






Taken with or without food No FE 0.84 4 
2020 Lefamulin Xenlet
a 
Taken on an empty stomach, at least 1 hour before or 
2 hours after a meal 
No FE  0.82 3 
2020 Pralsetinib Gavret
o 
Taken on an empty stomach (no food intake for at 
least 2 hours before and at least 1 hour after taking) 
Positive 2.22 2 
2020 Osilodrostat Isturisa Taken with or without food No FE  0.89 1 
2020 Filgotinib Jyselec
a 
Taken with or without food No FE  1 2 





 Tezacaftor   Positive  2.5-4
**
 2 
 Elexacaftor   No FE   1 4 
2020 Selumetinib  Koselu
go 
Take on an empty stomach. Do not consume food 2 
hours before each dose or 1 hour after each dose 
No FE  0. 62 4 
2020 Nifurtimox Lampit Taken with food Positive 1.71 2 
2020 Siponimod Mayze
nt 





Taken with or without food No FE  1 2 
2020 Darolutamide Nubeq
a 






Taken with or without food No FE  1 2 
 Ezetimibe   No FE  1  2 
2020 Azacitidine Onureg Take with or without food Negative 0.79 1 
2020 Elagolix Sodium Oriahn
n 
No instructions with regard to food intake Negative 0.75 3 
 Estradiol   No FE  1 1 
 Norethindrone 
Acetate 
  No FE  1.23  2 
2020 Alpelisib Piqray Taken immediately after food, at approximately the 
same time each day 






Taken with food Positive 1.88 2 
2020 Selpercatinib Retev
mo 
Taken with or without food No FE  1  















Taken with or without food Positive 1.66 4 























Avoid taking with food due to bitter taste  No FE  1 1 
2020 Enzalutamide Xtandi Taken with or without food  No FE  1  2 
2020 Ozanimod Zeposi
a 
Taken with or without food No FE  1 2 
2019 Isotretinoin Absoric
a Ld 
Taken with or without food No FE   1.2 2 
2019 Lumateperone 
Tosylate 
Caplyta Taken with food No FE  1.09 1 
2019 Ivabradine Corlan
or 










Take this medicine with water only. Avoid eating or 
drinking (except water) for 1 hour before, or 2 hours 
after taking. 
Negative 0.55 3 
2019 Lemborexant Dayvig
o 










Dovato Taken with or without food Positive 1.33  4  
 Lamivudine   No FE  1 3 





Taken with or without food No FE  0.9 4 
2019 Riluzole Xserva
n 
Taken at least 1 hour before or 2 hours after a meal No FE  0.85 2 
2019 Apalutamide Erlead
a 
Taken with or without food No FE  1 2 
2019 Colchicine Gloper
ba 
Taken with or without food No FE  0.93 3 
2019 Ledipasvir Harvon
i 
Taken with or without food  No FE  1 2 
 Sofosbuvir   Positive ~2 3 
2019 Fedratinib 
Hydrochloride 





Taken with or without food  No FE  1.05 4 
2019 Lusutrombopag Mulple
o 
Taken with or without food No FE  1 4 
2019 Istradefylline Nouria
nz 
Taken with or without food Positive 1.64 2 
2019 Voxelotor Oxbryt
a 




Taken with or without food No FE  1 4 
2019 Amifampridine Ruzurgi Taken with or without food No FE   1 3 
2019 Talazoparib Talzen
na 
Taken with or without food No FE  1 2 
2019 Elexacaftor Trikaft
a  







 Positive  2.5-4
**
 2 
 Tezacaftor   No FE  1 2 
2019 Pexidartinib 
Hydrochloride 
Turalio Taken on an empty stomach, at least 1 hour before or 
2 hours after a meal or snack 
Positive 2 2 




















Taken with or without food No FE   1 4 
2019 Larotrectinib Vitrakv
i 
Taken with or without food  No FE  1 1 
2019 Dacomitinib Vizimp
ro 
No instructions with regard to food intake No FE  1 2 
2019 Ceritinib Zykadi
a 





Taken once daily before the first meal of the day Positive 1.5 2 
2018 Brigatinib Alunbri
g 





Taken with food Positive 1.41  
2018 Bictegravir Biktarv
y 
Taken with or without food No FE  1.24 2 
 Emtricitabine   No FE  1 1 
 Tenofovir 
Alafenamide 
  Positive 1.64  3 
2018 Estradiol Bijuva Taken with food No FE  1 1 
 Progesterone   Positive 1.79 2 
       
2018 Encorafenib Braftov
i 
Taken with or without food No FE  1 2 
2018 Duvelisib Copiktr
a 
Taken with or without food Negative 0.63 4 
2018 Doravirine Delstri
go 
Taken with or without food No FE  1.1 2 




  Positive 1.27 3 
2018 Baloxavir 
Marboxil 
Xofluza Taken with or without food  No FE  0.64 2 
2018 Ibrutinib Imbruv
ica 
No instructions with regard to food intake Positive 2 2 
2018 Dolutegravir 
Sodium 
Juluca Taken with a meal Positive 1.87 4 
 Rilpivirine 
Hydrochloride 
  Positive 1.72 2 
2018 Tolvaptan Jynarq
ue 





Taken with food Positive 1.41  
2018 Binimetinib Mekto
vi 





Should be swallowed with water. In case of digestive 
intolerance, capsules should be taken during a meal. 
No FE  1 1 
2018 Neratinib Nerlyn
x 
Taken with food, preferably in the morning Positive 2.2 4 
2018 Omadacycline 
Tosylate 
Nuzyra Fast for at least 4 hours and then take  No FE  0.39 3 
2018 Elagolix Sodium Orilissa Taken with or without food No FE  0.76 3 
2018 Ivacaftor Orkam
bi 
Mixed with one teaspoon (5 mL) of age- Positive 3 2 
 Lumacaftor  appropriate soft food or liquid and the mixture 
completely consumed.  
 2 2 


















2018 Doravirine Pifeltro Taken with or without food No FE  1.16 2 
2018 Letermovir Prevy
mis 
Taken with or without food No FE  0.99 2 





Taken with or without food Positive 1.38 2 





Taken with or without food Negative 0.73 3 
2018 Ertugliflozin Steglat
ro 
Taken with or without food No FE  1 1 
2018 Ertugliflozin Stegluj
an 
Taken with or without food No FE  1 1 
 Sitagliptin   No FE  1 2 
2018 Ivacaftor  Symde
ko/Sy
mkevi 
Taken with fat-containing food Positive 3 2 
 Tezacaftor   No FE  1 2 
2018 Ivosidenib Tibsov
o 
Taken with or without food. Do not administer with a 
high fat meal due to increase in concentration 
Positive 1.98 2 
2018 Riluzole Tiglutik 
Kit 
Taken at least 1 hour before or 2 hours after a meal No FE  0.91 2 
2018 Tecovirimat Tpoxx Taken within 30 minutes after a full meal of moderate 
or high fat 
Positive 1.39 2 
2018 Abemaciclib Verzen
ios 
Taken with or without food No FE  1.09 3 
2018 Abiraterone 
Acetate 
Yonsa Taken with or without food Positive 4.4 4 
2017 Alectinib Alecen
sa 





Taken with food No FE  1 2 
2017 Betrixaban Bevyxx
a 





Taken with or without food No FE  1 2 
2017 Spironolactone Carospi
r 
Taken with or without food, but should be taken 
consistently with respect to food 
Positive 1.9 2 
2017 Allopurinol Duzallo Taken with food No FE  1 4 
 Lesinurad   No FE  1 2 
2017 Deflazacort Emflaz
a 
Taken with or without food. Tablet and Suspension No FE  1  





Taken with food No FE  3.64  
2017 Pirfenidone Esbriet Taken with food  No FE  0.84 1 





Taken with or without food No FE  0.87 1 
2017 Deferasirox Jadenu 
Sprinkl
e 










Taken after fasting for at least 8 hours Negative 0.51  




















Taken with or without food Negative 1 3 
2017 Glecaprevir Mavire
t 












Nikita Taken with or without food No FE  1 2 
2017 Ritonavir Norvir Should be mixed with soft food  Negative 0.51 4 
2017 Baricitinib Olumia
nt 
Taken with or without food No FE  0.86 3 
2017 Valsartan Prexxa
rtan 
No instructions with regard to food intake No FE 0.92 2 
2017 Cariprazine Reagila Taken with or without food No FE  1.12 2 





No instructions with regard to food intake No FE  1.23 3 





Taken with food No FE  1.20 3 
 Darunavir   Positive 1.52  2 
 Cobicistat   Positive 1.4 2 















Taken with or without food No FE  1 2 
2016 Brivaracetam Briviact Taken with or without food No FE  0.95 1 
2016 Emtricitabine Descov
y 
Taken with or without food No FE  1 1 
 Tenofovir 
Alafenamide 







Taken with or without food Positive 1.78 3 





Food should not be consumed at least 2 hours before 









Taken with or without food No FE  0.84 3 
 Lignagliptin   No FE  1 3 
2016 Palbociclib Ibranc
e 
Taken with food No FE  1.2 2 
2016 Lenvatinib 
Mesilate 
Kisplyx Taken at about the same time each day, with or 
without food 
No FE  1 2 
2016 Trifluridine Lonsurf No instructions with regard to food intake No FE  1 3 
 Tipiracil 
Hydrochloride 
  Negative 0.6 3 
2016 Sacubitril Neparv
is 
Taken with or without food No FE  1 4 
 Valsartan   No FE  1  2 
2016 Ixazomib Ninlaro Taken at least 1 hour before or at least 2 hours after 
food 
Negative 0.72 3 
2016 Pimavanserin Nuplazi Taken with or without food No FE  1.08  





















Ocaliva Taken with or without food No FE  1 2 
2016 Emtricitabine Odefse
y 
























Should not eat food for 1 hour before and for at least 1 
hour after intake. 
Negative 0.69 2 




  No FE  1 3 
2016 Dronabinol Syndro
s 
Administer the first dose on an empty stomach at least 
30 minutes before eating. Subsequent doses can be 
taken without regard to meals. 





Taken with or without food No FE  1.06 3 
2016 Eluxadoline Truber
zi 
Taken with food Negative 0.4 3 
2016 Selexipag Uptravi Taken with food No FE  1.1 2 
2016 Venetoclax Vencly
xto 








Taken with or without food No FE  0.89 2 
 Grazoprevir   Positive 1.5 2 
 
  
         
 
Table 2: Overview of the Support Vector Machine (SVM) and Artificial Neural Network (ANN) machine learning 
models produced in this study, detailing the inputs, model architecture and the comparative overall accuracies 



















C value: 16.68 
72% 69% 
ANN Dose, HBD, S+logP, 
T_PSA 
1 hidden layer 
13 hidden nodes 
82% 72% 
         
